大型血管における薬物放出ボールと薬剤活性ステント: 形態学的分析および血管運動機能 (DEBORA 研究) 大型血管における形態学的分析および血管運動機能 (DEBORA 研究)
大型血管における薬物放出ボールと薬剤活性ステント: 形態学的分析と血管運動機能 (DEBORA 研究)
Randomized, controlled, open and multicenter study that analyzes the vasomotor function 8 months after use of the drug-eluting balloon (DCB) vs. drug-eluting stent (DES) in vessels ≥ 3.5 mm
調査の概要
詳細な説明
Randomized, controlled, open and multicenter study that analyzes the vasomotor function 8 months after use of the drug-eluting balloon (DCB) vs. drug-eluting stent (DES) in vessels ≥ 3.5 mm
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:FUNDACION EPIC
- 電話番号:0034987876135
- メール:iepic@fundacionepic.org
研究連絡先のバックアップ
- 名前:IÑIGO LOZANO MARTINEZ-LUENGAS, MD, PhD
- 電話番号:0034630901145
- メール:inigo.lozano@fundacionepic.org
研究場所
-
-
-
Barcelona、スペイン、08035
- 募集
- Hospital Universitari Vall d'Hebron
-
Gijón、スペイン、33394
- 募集
- Hospital Universitario de Cabueñes
-
Huelva、スペイン、21005
- 募集
- Hospital Universitario Juan Ramón Jiménez
-
León、スペイン、24008
- 募集
- Hospital Universitario de Leon
-
Lugo、スペイン、270003
- 募集
- Hospital Universitario Lucus Augusti
-
Mérida、スペイン、06800
- 募集
- Hospital de Merida
-
Oviedo、スペイン、33011
- 募集
- Hospital Universitario Central de Asturias
-
Pontevedra、スペイン、36071
- 募集
- Hospital Provincial de Pontevedra
-
Tarragona、スペイン、43005
- 募集
- Hospital Universitari de Tarragona Joan XXIII
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
Patients who meet all of the following conditions are included.
- Patients aged ≥ 18 years and;
- Patients with chronic coronary syndrome, acute coronary syndrome without ST segment elevation or acute coronary syndrome with elevation ST segment in non-culprit lesions 48 hours after the event and;
- Patients with de novo lesions in vessels ≥ 3.5 mm without calcification significant no visible thrombus and;
- Patients who have been informed of the characteristics of the study and have provided their written informed consent.
Exclusion Criteria:
Patients who meet at least one of the following conditions are excluded:
- Patients with any contraindication for the administration of acetylcholine (ACh) or nitroglycerin (NTG).
- Patients with a history of coronary vasospasm or spontaneous dissection of the coronary artery.
- Patients with significant medical, surgical or psychiatric condition that would affect the safety of the subject or influence the outcome of the study according to the doctor's opinion.
- Patients who received a combination of DES and DCB in the same vessel
- Patients with glomerular filtration rate <30 ml/min/ 1.73 m2
- Patients with body mass index >35 (may affect the evaluation qualitative diameter of the coronary artery).
- Patients with symptomatic congestive heart failure.
- Patients with significant autoimmune inflammatory conditions and patients taking immunomodulatory medications (including methotrexate, cyclosporine, steroids).
- Patients with heart transplant.
- Patients with anemia (Hb <12 g/dL in men and <10 g/dL in women).
- Patients, women of childbearing age with a positive pregnancy test.
- Pregnant female patients.
- Patients included in other clinical trials with active follow-up.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Drug Coated Balloon (DCB)
Drug Coated Balloon (DCB) |
Drug Coated Balloon (DCB) in patients with indication of Percutaneous Coronary Intervention (PCI) |
|
実験的:Drug Eluting Stent (DES)
Drug Eluting Stent (DES) |
Drug Eluting Stent (DES) in patients with indication of Percutaneous Coronary Intervention (PCI) |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of vessels with a positive response to Ach, defined as >4% change in the mean luminal diameter observed in the coronary segment distal (10-30 mm) to the treated segment, after the infusion of the maximum dose of ACh (10-6 mol/L).
時間枠:8 months
|
Percentage of vessels with a positive response to Ach, defined as >4% change in the mean luminal diameter observed in the coronary segment distal (10-30 mm) to the treated segment, after the infusion of the maximum dose of ACh (10-6 mol/L). |
8 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Comparison of percentage of angiographic restenosis by quantitative coronary
時間枠:8 months
|
Comparison of percentage of angiographic restenosis by quantitative coronary |
8 months
|
|
Comparison of the minimum luminal diameter of the treated segment by optical coronary tomography
時間枠:8 months
|
Comparison of the minimum luminal diameter of the treated segment by optical coronary tomography |
8 months
|
|
Comparison of the minimum luminal area of the treated segment by optical coronary tomography
時間枠:8 months
|
Comparison of the minimum luminal area of the treated segment by optical coronary tomography |
8 months
|
|
Percentage of of strut coverage by OCT(Optical Coherence Tomography) in the DES group
時間枠:8 months
|
Percentage of of strut coverage by OCT in the DES group |
8 months
|
|
Percentage of vessels with normal vascular architecture with correct definition of intima and media by optical coherence tomography in the drug-coated balloon group at 8 months
時間枠:8 months
|
Percentage of vessels with normal vascular architecture with correct definition of intima and media by optical coherence tomography in the drug-coated balloon group at 8 months |
8 months
|
協力者と研究者
スポンサー
出版物と役立つリンク
一般刊行物
- Yerasi C, Case BC, Forrestal BJ, Torguson R, Weintraub WS, Garcia-Garcia HM, Waksman R. Drug-Coated Balloon for De Novo Coronary Artery Disease: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020 Mar 10;75(9):1061-1073. doi: 10.1016/j.jacc.2019.12.046.
- Nakamura T, Brott BC, Brants I, Panchal D, Li J, Chen JP, King SB 3rd, Chronos N, Hou D. Vasomotor function after paclitaxel-coated balloon post-dilation in porcine coronary stent model. JACC Cardiovasc Interv. 2011 Feb;4(2):247-55. doi: 10.1016/j.jcin.2010.08.028.
- Gutierrez E G-LJ, Escaned J, Cruz I, Ojeda S, Romaguera R, Moreno R. Valoración de la función endotelial y provocación de vasoespasmo coronario mediante infusión intracoronaria de acetilcolina. Documento técnico de la ACI-SEC. REC Interv Cardiol. 2021;3(4):286-296.
- Gomez-Lara J, Oyarzabal L, Ortega-Paz L, Brugaletta S, Romaguera R, Salvatella N, Roura G, Rivero F, Fuentes L, Alfonso F, Otaegui I, Vandeloo B, Vaquerizo B, Sabate M, Comin-Colet J, Gomez-Hospital JA. Coronary Endothelium-Dependent Vasomotor Function After Drug-Eluting Stent and Bioresorbable Scaffold Implantation. J Am Heart Assoc. 2021 Nov 16;10(22):e022123. doi: 10.1161/JAHA.121.022123. Epub 2021 Nov 3.
- Brugaletta S, Heo JH, Garcia-Garcia HM, Farooq V, van Geuns RJ, de Bruyne B, Dudek D, Smits PC, Koolen J, McClean D, Dorange C, Veldhof S, Rapoza R, Onuma Y, Bruining N, Ormiston JA, Serruys PW. Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy? Eur Heart J. 2012 Jun;33(11):1325-33. doi: 10.1093/eurheartj/ehr466. Epub 2012 Apr 16.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。